Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hypoxia × Radiotherapy × CNS × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Gastrointestinal 1 CNS 1

Conditions

Glioblastoma 187 Central Nervous System Neoplasms 114 Brain Neoplasms 97 Gliosarcoma 80 Glioma 60 Astrocytoma 59 Oligodendroglioma 32 Neuroblastoma 24 Neoplasm Metastasis 18 Medulloblastoma 18 Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 11 Breast Neoplasms 11 Diffuse Intrinsic Pontine Glioma 10 Ependymoma 9 Meningeal Carcinomatosis 8 Neoplasms 7 Lymphoma 7 Neuroectodermal Tumors, Primitive 6 Lymphoma, Follicular 6 Burkitt Lymphoma 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Recurrence 5 Prostatic Neoplasms 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Optic Nerve Glioma 5 Lymphoma, Large B-Cell, Diffuse 5 Esthesioneuroblastoma, Olfactory 5 Dendritic Cell Sarcoma, Interdigitating 5

Interventions

Temozolomide 1 Sodium Chloride 1 Saline Solution 1 Radiotherapy 1 Injections 1 Ferrosoferric Oxide 1 Dexmedetomidine 1 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06477939 2024-06-27

THREE-GLEES

Institut de cancérologie Strasbourg Europe

Phase 3 Not yet recruiting

Hypoxia, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡